JAK2 and neoplasm: Whole exome sequencing of refractory melanoma tumor lesions of patients initially responding to anti–programmed death 1 (PD-1) therapy revealed loss-of-function mutations in the IFNyR-associated genes Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2).